Cure8 research brief
People with IBD face higher osteoporosis risk; this study looked for a genetic variant (LCT-13910C>T) that might affect bone density but found no clear link in this cohort, so it does not change current bone-health management for IBD patients.
Patients with IBD worried about bone density; gastroenterologists, endocrinologists/osteoporosis specialists; researchers in IBD genetics and bone health.
This study tested whether the LCT-13910C>T (rs4988235) variant near MCM6 (a marker used for lactase persistence/intolerance) is linked to bone mineral density (BMD) in people with IBD. Researchers measured BMD at the lumbar spine (L1–L4) and femoral neck, genotyped patients and controls, and compared groups.
The main finding reported is that overall the LCT-13910C>T polymorphism was not independently associated with BMD in this cohort of 125 IBD patients and 39 controls. One subgroup result—higher femoral neck BMD in CT versus CC genotypes among Crohn’s disease patients—was noted, but the authors describe the analysis as exploratory.
The paper highlights moderate sample size and lack of adjustment for some key confounders.
If you read the paper: it reports methods (HRM genotyping with Sanger confirmation) and measured biochemical parameters alongside BMD, but does not provide definitive evidence to change clinical care regarding genetic testing for lactase persistence when assessing osteoporosis risk in IBD.
Results are from an abstract/full-text summary and described by the authors as exploratory. Sample size is moderate and analyses did not control for some key confounders, so findings require confirmation in larger, better-controlled studies.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A genetic marker (HLA-DRB1*01:03) was linked to more severe IBD outcomes—higher rates of colectomy/colonic surgery, more perianal disease, earlier use and higher failure of advanced therapies—which could help explain...
The work identifies a genetic link (HLA‑DRB1*01:03) to anti‑IL‑10 autoantibodies and describes a small subgroup of IBD patients who may have a distinct immune mechanism driving disease—information that could matter for...
The study suggests measurable retinal and choroidal microvascular differences in people with IBD versus controls, which could point to systemic vascular effects of inflammation and offer noninvasive biomarker...
